International Mesothelioma Program
The Program is built on the existing multidisciplinary team collaborating on mesothelioma research and treatment: Brigham and Women’s Hospital - Division of Thoracic Surgery and the Departments of Anesthesiology, Dermatology, Pathology and Radiology; Dana-Farber Cancer Institute - Departments of Medical and Radiation Oncology; Department of Society, Human Development, and Health; Pain and Palliative Care Service; and the Thoracic Oncology Program; Harvard School of Public Health - Departments of Environmental Health and Cancer Cell Biology; Massachusetts General Hospital – Biostatistics Center.
The Program is built on the existing multidisciplinary team collaborating on mesothelioma research and treatment: Brigham and Women’s Hospital - Division of Thoracic Surgery and the Departments of Anesthesiology, Dermatology, Pathology and Radiology; Dana-Farber Cancer Institute - Departments of Medical and Radiation Oncology; Department of Society, Human Development, and Health; Pain and Palliative Care Service; and the Thoracic Oncology Program; Harvard School of Public Health - Departments of Environmental Health and Cancer Cell Biology; Massachusetts General Hospital – Biostatistics Center.
The research interests of the program investigators span the range from basic MPM biology and target discovery (growth control, over-expressed genes, and expression of SV40 large T antigen) to clinical treatment of MPM (diagnosis, pathology, surgical techniques, improvements in treatment, outcome, and patterns of recurrence). Collaborations among the investigators have resulted in fourteen joint publications since 1993, as well as publications from the individual groups.
Founded by David J. Sugarbaker, MD, the International Mesothelioma Program (IMP) encompasses both a clinical program and a research program. Our clinical focus is on developing treatment strategies that can significantly extend the life of our patients. Ultimately, the objective of the program is to offer potentially curative therapy to patients with
mesothelioma.
Tidak ada komentar:
Posting Komentar